TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Treating younger patients with TAVR increases risk of death

Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely. 

Newsweek ranked the 50 best heart hospitals in the world

Cardiologist demand is on the rise—can hospitals keep up?

Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind. 

Thumbnail

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.

Philippe Genereux explains how EARLY TAVR will help raise awareness for undertreatment of TAVR.

New data put a spotlight on troubling TAVR trends

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

Philippe Genereux, MD, explains the details of the EARLY TAVR trial, which compared early interventions vs. waiting in patients with asymptomatic severe aortic stenosis.

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

A Da Vinci Xi robot from California-based Intuitive Surgical. Researchers used these robotic surgical systems to help guide AVR in low- and intermediate-risk patients who presented with severe AS.

Robotic aortic valve replacement may offer certain benefits over TAVR

Robotic-assisted aortic valve surgery may be a safe, effective alternative to TAVR when treating low- and intermediate-risk patients. A new analysis in The Annals of Thoracic Surgery explored this topic at length.

Video with JACC Editor Harlan Krumholtz offering an overview of key tricuspid and TAVR late-breakers at TCT24.

Progress in tricuspid valve care and TAVR on full display at TCT 2024

Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific TAVR valve comes up short in comparison with Medtronic, Edwards devices

The Acurate neo2 TAVR valve has been used to treat severe aortic stenosis in other parts of the world for years. In the United States, however, the device has still not been approved for commercial use.  

Displaying 1 - 8 of 401
Design by Adaptive Theme